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Prostaglandin (PG) E2, a major product of activated
macrophages, has been implicated in atherosclero-
sis and plaque rupture. The PGE2 receptors, EP2
and EP4, are expressed in atherosclerotic lesions
and are known to inhibit apoptosis in cancer cells.
To examine the roles of macrophage EP4 and EP2
in apoptosis and early atherosclerosis, fetal liver
cell transplantation was used to generate LDLR/
mice chimeric for EP2/ or EP4/ hematopoietic
cells. After 8 weeks on a Western diet, EP4/ /
LDLR/ mice, but not EP2/ / LDLR/ mice,
had significantly reduced aortic atherosclerosis
with increased apoptotic cells in the lesions. EP4/
peritoneal macrophages had increased sensitivity to
proapoptotic stimuli, including palmitic acid and free
cholesterol loading, which was accompanied by
suppression of activity of p-Akt, p-Bad, and NF-kB-
regulated genes. Thus, EP4 deficiency inhibits the
PI3K/Akt and NF-kB pathways compromising
macrophage survival and suppressing early athero-
sclerosis, identifying macrophage EP4-signaling
pathways as molecular targets for modulating the
development of atherosclerosis.
INTRODUCTION
Atherosclerosis, the underlying cause of coronary heart disease
and stroke, is a complex degenerative process including an im-
portant inflammatory component (Ross, 1999). All of the major
cell types involved in atherogenesis produce eicosanoids, and
mounting evidence supports critical roles for the prostaglandins
and their specific receptors in atherogenesis and plaque stabil-
ity. Much attention has been given to the roles of prostacyclin
(PGI2) and thromboxane A2 (TXA2) and their receptors in athero-
thrombosis (Grosser et al., 2006). Genetic deletion of the PGI2 re-
ceptor accelerates the neointimal proliferation in response to
vascular injury (Cheng et al., 2002), whereas deletion of the
TXA2 receptor reduces atherosclerosis in apoE-null mice (Ko-492 Cell Metabolism 8, 492–501, December 3, 2008 ª2008 Elsevierbayashi et al., 2004). Although eicosanoids have been implicated
in atherogenesis and plaque stability (Egan et al., 2005; Linton
and Fazio, 2008), the roles of PGE2 and its specific prostanoid re-
ceptors in atherogenesis have not been examined directly.
Macrophages are the major cell type of early atherosclerotic
lesions, and their activation by a variety of stimuli results in abun-
dant COX-mediated production of PGE2. Acting in an autocrine
and paracrinemanner, PGE2modulates inflammatory responses
via a family of four membrane-spanning G protein-coupled re-
ceptors termed EP1, EP2, EP3, and EP4 (Breyer et al., 2001). Hu-
man atherosclerotic plaque cells have been reported to express
EP4 and EP2 (Go´mez-Herna´ndez et al., 2006). Interestingly,
platelet EP3 expression has recently been shown to promote
thrombosis in response to vascular PGE2 production induced
by injury of carotid arteries in apoE-deficient mice (Gross et al.,
2007). Deletion of EP2 promotes salt-sensitive hypertension in
mice fed a very high sodium diet (Kennedy et al., 1999), whereas
EP4 has been shown to be the primary mediator of anti-inflam-
matory effects of PGE2 and a regulator of chemokine production
in vitro (Takayama et al., 2002, 2006). The EP4 receptor has been
reported to be responsible for the PGE2-mediated increase in
matrix metalloproteinases (MMPs) in macrophages (Pavlovic
et al., 2006) that may initiate unstable plaques. Together, these
data suggest that macrophage EP2 and EP4 receptor activity
may play important roles in the pathogenesis of atherosclerosis.
PGE2 modulates apoptosis predominantly through the EP2
and EP4 receptors (Chun et al., 2007; Tessner et al., 2004; Vas-
siliou et al., 2004), yet the role of PGE2-mediated apoptosis in
arterial macrophages has not been defined. Though EP2 and
EP4may have redundant functions, they employ different signal-
ing pathways. Both EP2 and EP4 mediate signaling via cAMP-
dependent protein kinase (PKA), leading to the phosphorylation
of the cAMP-responsive element binding protein, which is known
to regulate Bcl-2 (Regan, 2003), glycogen synthase kinase, and
Bad (Fujino et al., 2003; Lizcano et al., 2000). In addition, EP4
has been reported to activate a phosphoinositide-3-kinase
(PI3K) that in turn activates Akt, also known as protein kinase
B (PKB). Akt inhibits cell-death pathways by directly phosphory-
lating and inactivating proteins involved in apoptosis, including
Bad, procaspase 9, and members of the Forkhead proinflam-
matory family (Brunet et al., 1999; Cardone et al., 1998; Datta
et al., 1997). Akt also regulates the NF-kB pathway, changing
its antiapoptotic and proinflammatory functions (Madrid et al.,Inc.
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cently, PGE2 has been reported to modulate LPS-induced acti-
vation of NF-kB by a novel EP4-receptor-associated protein
(Minami et al., 2008). Thus, activation of EP4 may modulate
signaling pathways, regulating macrophage survival and inflam-
matory functions in atherosclerosis that are distinct from those
of EP2.
The goal of the current study was to examine the roles of mac-
rophage EP2 and EP4 receptors in apoptosis and atherogenesis
in vivo.Given the fact thatmicewith targeteddeletionof EP4gene
die soon after birth (Nguyen et al., 1997; Schneider et al., 2004;
Segi et al., 1998), we used the approach of fetal liver cell trans-
plantation (Babaev et al., 1999) to generate LDLR/mice chime-
ric for expression of EP2 and EP4 by hematopoietic cells. Our
data demonstrate that the absence of EP4 in hematopoietic cells
promotes macrophage apoptosis through downregulation of
PI3K and NF-kB signaling pathways, and this is associated with
significantly suppressed early atherosclerosis in LDLR/mice.
RESULTS
Generation of Mice with EP4- or EP2-Null
Hematopoietic Cells
Because EP4-null mice die soon after birth (Nguyen et al., 1997;
Schneider et al., 2004; Segi et al., 1998), we used fetal liver cell
(FLC) transplantation to generate mice chimeric for gene dele-
tions of EP2 or EP4 in their hematopoietic cells (Babaev et al.,
1999). Eight-week-old female LDLR/mice were lethally irradi-
ated and transplanted with female wild-type (WT; n = 12), EP4/
(n = 13), or EP2/ (n = 13) FLC. Twelve weeks posttransplanta-
tion, peritoneal macrophages were isolated from recipient mice,
and EP4 and EP2 gene expression were analyzed by real-time
PCR. The results indicate a complete change in the genotype
to the donor types with a compensatory increase of EP4
mRNA expression levels in EP2/ cells and no changes in
EP2 gene expression in EP4/ macrophages (Figures 1A and
1B). Interestingly, LPS treatment for 5 hr significantly suppressed
both EP4 and EP2 gene-expression levels in all types of macro-
phages (Figures 1A and 1B).
Since EP2 or EP4 receptor activity may affect COX production
(Fujino et al., 2003), we measured COX-1 and COX-2 expression
in the peritoneal macrophages from LDLR/mice reconstituted
with EP2/, EP4/, orWTmacrophages. COX-1 gene and pro-
tein expression levels were similar in all three types of cells (Fig-
ures 1C and 1E). In contrast, EP4/ macrophages had signifi-
cantly lower levels of LPS-induced COX-2 gene expression
than WT or EP2/ macrophages (Figure 3D). COX-2 protein
expression was detected only in LPS-treated cells and was
slightly lower (17%) in EP4/ macrophages compared to WT
and EP2/ cells (Figure 1F).
EP4 Deficiency in Hematopoietic Cells Suppresses
Early Atherosclerosis and Increases Apoptosis
in Atherosclerotic Lesions
Four weeks posttransplantation, the recipient mice were chal-
lenged with the Western diet for 8 weeks. There were no statis-
tically significant differences in serum total cholesterol and tri-
glyceride levels between the three groups of recipient mice
reconstituted with WT, EP4/, or EP2/ FLC on the chow orCellatherogenic diets (Table S1). Analysis of the serum samples by
size-exclusion chromatography revealed an accumulation of
cholesterol in VLDL, LDL, and IDL fractions with no differences
between mice reconstituted with WT, EP4/, or EP2/ FLC
(Figure 2A).
To evaluate the extent of atherosclerotic lesions, we utilized
two alternative methods: analysis of atherosclerotic lesions en
face in whole aortas and cross sections of the aortic sinus. En
face analysis demonstrated that LDLR/ mice reconstituted
with EP4/ FLC had significantly smaller (57%) lesions com-
pared to mice transplanted with WT or EP2/ FLCs (1.5% ±
0.2% versus 2.6% ± 0.6% and 2.5% ± 0.5%, respectively; Fig-
ures 2B and 2C). Similarly, mice reconstituted with EP4/
FLCs had smaller atherosclerotic lesions in the proximal aortas
than mice transplanted with WT or EP2/ FLC (322461 ±
34555mm2versus452708± 14407mm2and358179± 35133mm2,
respectively; p < 0.05 versus WT; Figure 2D). Although there
appeared to be a trend for a reduction in atherosclerosis in
the EP2// LDLR/mice, the difference was not statistically
significant versus WT/ LDLR/ mice or EP4// LDLR/
mice.
Figure 1. EP2 Deficiency Causes a Compensatory Increase in EP4
Gene-Expression, and EP4 Deficiency Suppresses COX-2 Produc-
tion in Peritoneal Macrophages
(A–D) EP4 (A), EP2 (B), COX-1 (C), and COX-2 (D) gene-expression levels in
peritoneal macrophages isolated from LDLR/ mice reconstituted with WT
(black), EP4/ (white), or EP2/ (gray) FLC and fed with the Western diet
for 8 weeks. Macrophages were treated with media alone (control) or with
LPS (50 ng/ml) for 5 hr. The gene-expression levels were measured by
real-time PCR. Graphs represent data (mean ± SEM) with the same number
(n = 3) of mice per group (*p < 0.05 between control and treated with LPS cells
of the same group, and between WT and EP4/ cells by one-way ANOVA
analysis).
(E–F) COX-1 (E) and COX-2 (F) protein levels in peritoneal macrophages. Mac-
rophages were treated with media alone or with LPS for 5 hr. Cell extract
(20 mg/line) was resolved on 10% Bis-Tris gel and analyzed by western blot.Metabolism 8, 492–501, December 3, 2008 ª2008 Elsevier Inc. 493
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mediate cell survival effects in dendritic cells and epithelial cells
(Chun et al., 2007; Tessner et al., 2004; Vassiliou et al., 2004), we
examined whether EP4 might modulate apoptosis in atheroscle-
rotic lesions. Therefore, we stained serial sections (n = 6/aorta)
from the proximal aorta with a terminal deoxynucleotidyl trans-
ferase-mediated dUTP nick-end-labeling (TUNEL). Mice recon-
stituted with EP4/ FLC had an increased (160%) percentage
of TUNEL-positive (TUNEL+) cells in atherosclerotic lesions
compared to mice transplanted with WT FLC (Figures 3A and
3B). This was accompanied by a strong trend for a decrease in
the number of nuclei in the atherosclerotic lesions (p = 0.06)
(Figure 3C) stained with macrophage-specific antibody
MOMA-2 in combination with DAPI as described (Babaev
et al., 2005). Mice reconstituted with EP2/ FLC had a similar
trend for increased numbers of TUNEL+ cells that was not statis-
tically significant (by a one-way ANOVA). Thus, EP4 deficiency in
hematopoietic cells does not affect plasma lipid levels but signif-
icantly suppresses early atherosclerosis and increases apopto-
sis in atherosclerotic lesions.
Macrophage EP4 Deficiency Increases Sensitivity
to Apoptotic Stimuli
Next we examined in vitro the impact of deficiency of EP2 or EP4
on macrophage sensitivity to apoptosis. To generate cells for
these studies, we lethally irradiated and transplanted C57BL6
mice with WT (n = 16), EP4/ (n = 14), and EP2/ (n = 12)
Figure 2. EP4 Deficiency in Hematopoietic
Cells Does Not Affect Plasma Lipid Levels
but Significantly Suppresses Early Athero-
sclerosis
(A) FPLC profiles in LDLR/ mice reconstituted
WT (black), EP4/ (white), or EP2/ (gray)
FLCs. The data are represented as the average
of total cholesterol of mice (n = 3 per group) recon-
stituted with different FLC and fed with the West-
ern diet for 8 weeks. Fractions 14–17 contain
VLDL, fractions 18–24 are IDL/LDL, and fractions
25–30 contain HDL.
(B–D) Atherosclerotic lesions in aorta en face (B)
and extent of atherosclerotic lesion area in the dis-
tal (C) and proximal (D) aortas of LDLR/mice re-
constituted WT (black), EP4/ (white), or EP2/
(gray) FLCs. Graphs represent data with different
numbers (n = 12, 13, and 13, respectively) of mice
of each genotype (p < 0.05 between control and
reconstituted with EP4/ FLC groups by one-
way ANOVA analysis, the Tukey test).
FLCs. Ten weeks posttransplantation,
thioglycollate-elicited peritoneal macro-
phages were isolated from these mice
and treated with 0.5 mM palmitic acid
(PA), a stress-mediated lipotoxic factor
that rapidly increases saturated lipid con-
tent in the rough endoplasmic reticulum
(ER), inducing ER stress, which triggers
apoptotic cell death (Borradaile et al.,
2006). PA complexed with BSA treatment
increased TUNEL+ cell numbers in all cell
types (Figures 4B–4D) with a significantly higher percentage in
EP4/ macrophages than in EP2/ and WT cells (Figure 4E).
Remarkably, compared to WT and EP2/ cells, EP4/macro-
phages also showed enhanced sensitivity to different stimuli, in-
cluding free cholesterol loading with acetylated LDL in combina-
tion with an ACAT inhibitor (Yao and Tabas, 2001), or oxidized
LDL (Figure 4F), or a specific inhibitor of IkB phosphorylation,
BAY 11-7082 (20 mM), that decreases expression of NF-kB
(Figure S1A). Thus, EP4 deficiency in macrophages significantly
increases their sensitivity to apoptosis.
PI3K/Akt Signaling Pathway Is Affected in EP4-Null
Macrophages
To define the molecular mechanisms responsible for EP4-medi-
atedmacrophage apoptosis, we examined whether sensitivity to
apoptosis in EP4/macrophages is associated with changes in
signal transduction pathways. EP4/, EP2/, and WT perito-
neal macrophages were treated with PA-BSA for 3, 6, or 18 hr,
and the activity of Akt and Bad signal proteins, as indicated by
phosphorylation, were analyzed by western blot. EP4/macro-
phages had significantly decreased levels of basal and stimu-
lated p-Akt, whereas EP2/ cells had suppression of only stim-
ulated p-Akt (Figure 4G). In contrast, Akt levels varied
insignificantly, and p-GSK3a/b and b-actin protein levels were
similar in the three cell types (Figure 4G). In addition, compared
to WT cells, EP4/ macrophages had completely abolished
phosphorylation of Bad (serine 136 and 155) after 3 hr of494 Cell Metabolism 8, 492–501, December 3, 2008 ª2008 Elsevier Inc.
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after 18 hr of treatment. This suppression of p-Akt and p-Bad ac-
tivity in EP4/ macrophages indicates that the PI3K/Akt path-
way may be responsible for the increase in apoptosis.
To test this hypothesis, we treated WT macrophages with PA-
BSA alone or with different cAMP agonists, including dibutyryl
cAMP or a type IV phosphodiesterase inhibitor, RO-20-1724,
for 3 and 6 hr. Stimulation of the cAMP pathway with dibutyryl
cAMP and, to a lesser extent, with RO-20-1724, significantly
suppressed phosphorylation of Akt (Figure 5A). The dibutyryl
cAMP also suppressed the phosphorylation of Bad155. Treat-
ment with a PKA inhibitor, H89, had only minor effects on phos-
phorylation of Akt and Bad (Figure 5A).
In contrast, treatment of WT macrophages with a potent PI3K
inhibitor, wortmannin (Wrt, 100 nM), alone or in combination with
PA-BSA for 3 and 6 hr, completely abolished p-Akt activation
(Figure 5B). Interestingly, more prolonged treatment with PA-
BSA together with Wrt (50 nM) for 18 hr increased the number
of apoptotic cells (Figure 5C) producing a dramatic cell loss
(70%), possibly due to the role of the PI3K/Akt pathway in
cell attachment and migration (Shiojima and Walsh, 2002). This
may explain the decrease in the percentage of TUNEL+ cells in
the group treated with PA-BSA together and Wrt compared to
the treatment with PA-BSA alone (Figure 4D).
Finally, to examine whether decreased Akt activation is re-
sponsible for enhanced apoptosis in macrophages, we treated
WT cells with PA-BSAwith or without a cell-permeable Akt inhib-
itor IV, which does not affect PI3K. This inhibitor acted as a proa-
poptotic factor and significantly (>2-fold) increased apoptotic
cell numbers when combined with PA-BSA compared to PA-
BSA alone (Figure 5I). The analysis of the signaling pathway
demonstrated that the Akt inhibitor alone or in combination
with PA-BSA completely eliminated Akt phosphorylation without
affecting Akt and b-actin (Figure 5H). Together these results
demonstrate that the PI3K/Akt signaling pathway is suppressed
in EP4-null macrophages, leading to increased apoptosis.
EP4 Deficiency Suppresses the NF-kB Pathway
Since Akt directly regulates the activity of the transcription factor
NF-kB (Madrid et al., 2000; Ozes et al., 1999; Romashkova and
Makarov, 1999), we examined whether macrophage EP4 defi-
ciency has an impact on inflammatory and antiapoptotic genes.
Figure 3. EP4 Deficiency in Hematopoietic Cells Increases Apopto-
sis in Atherosclerotic Lesions
(A) Distribution of TUNEL+ cells in the proximal aorta of mice reconstitutedwith
different FLC and fed with the Western diet for 8 weeks (20x magnification).
The scale bars represent 20 mm.
(B and C) Percent of TUNEL+ cells (B) and numbers of DAPI-stained nucleus
cells/MOMA-2+ area (C) in atherosclerotic lesions of LDLR/ mice reconsti-
tuted with WT (black), EP4/ (white), or EP2/ (gray) FLC and fed with the
Western diet for 8 weeks. Graphs represent data (mean ± SEM) with different
numbers (n = 12, 13, and 13, respectively) of mice per group (*p < 0.05 between
mice reconstituted with WT and EP4/ cells by one-way ANOVA analysis).
Figure 4. EP4 Deficiency in Macrophages
Increases Susceptibility to Apoptosis and
Suppresses Akt and Bad Phosphorylation
(A–D) Detection of TUNEL+ cells in untreated WT
(A) and treated with PA-BSA (0.5 mM for 18 hr),
WT (B), EP4/ (C), or EP2/ (D) macrophages
(x20).
(E and F) Percent of TUNEL+ cells in WT (black),
EP4/ (white), or EP2/ (gray) macrophages
untreated or treated with PA-BSA (E), oxLDL
(100 mg/ml) or AcLDL (100 mg/ml) plus an ACAT in-
hibitor, Sandoz 58035 (10 mg/ml) (F) for 24 hr.
Graphs represent data (mean ± SEM) with the
same number (n = 3) of mice per group (*p < 0.05
between WT and EP4/ cells by one-way
ANOVA analysis).
(G and H) Expression of Akt, p-Akt (serine 473),
and p-GSK3a/b (H), p-Bad (serine 136 and 155),
and b-actin (J) in WT, EP4/ or EP2/ peritoneal
macrophages that were untreated or treated with
PA-BSA (0.5 mM) for 3, 6, or 18 hr. Cell extract
(100 mg/line) was resolved and analyzed by west-
ern blot using antibodies against the proteins as
indicated.Cell Metabolism 8, 492–501, December 3, 2008 ª2008 Elsevier Inc. 495
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in WT Macrophages Accelerates Apoptosis
(A) Expression of Akt, p-Akt (serine 473), Bad (serine 136 and
155), and b-actin proteins in WT macrophages treated with
PA-BSA (0.5 mM) alone or with dibutyryl cAMP (1 mM),
RO-20-1724 (100 mM), or PKA inhibitor, H89 (10 mM), for
3 and 6 hr.
(B) Expression of Akt, p-Akt, GKS3a/b and b-actin proteins in
WT macrophages treated with PA-BSA alone or with wort-
mannin (Wrt, 100 nM) for 3 or 6 hr. Extracted proteins
(100 mg/lane) were resolved and analyzed by western blot
using antibodies against the proteins as indicated.
(C–F) Apoptosis in WT macrophages untreated (C) or treated
with Wrt (50 nM; D) or PA-BSA (E) alone or in combination
with Wrt (F) macrophages for 18 hr (x20). The scale bars rep-
resent 20 mm.
(G) Percent of apoptotic macrophages untreated and treated
with Wrt (50 nM; D), PA-BSA alone or in combination with
Wrt for 18 hr. Graphs represent data (mean ± SEM) with the
same number (n = 3) of mice per group (*p < 0.05 between un-
treated cells and treated with PA-BSA alone and with Wrt by
one-way ANOVA analysis).
(H–K) Apoptosis in WT macrophages untreated (H) or treated
with the Akt inhibitor IV (10 mM; I) or PA-BSA (J) alone or in
combination with the Akt inhibitor IV (K) for 24 hr (x20). The
scale bars represent 20 mm.
(L) Percent of apoptotic macrophages untreated and treated
with the Akt inhibitor IV (10 mM), PA-BSA alone or in combina-
tion with the Akt inhibitor IV for 24 hr (*p < 0.05 between cells
treated with PA-BSA alone and with the Akt inhibitor by one-
way ANOVA analysis, the Tukey test).
(M) Expression of Akt, p-Akt, and b-actin in WT macrophages
treated with Akt inhibitor IV or PA-BSA alone or in combination
for 6 hr. Extracted proteins (100 mg/lane) were resolved and
analyzed by western blot using antibodies against the proteins
as indicated.Peritoneal macrophages were stimulated with LPS (50 ng/ml) for
5 hr and the expression pattern of the genes was analyzed by
real-time PCR. There were no differences in the expression
levels of TNFa, Gro1, and MMP-2 genes between WT, EP4/,
and EP2/ macrophages. However, EP4/ macrophages
had significantly decreased expression levels of inflammatory
(IL1b, IL6, MCP-1, and MMP9), NF-kB-related (p50, IKKa, and
IKKb), and antiapoptotic (Gadd45 and Itch) genes compared to
WT and EP2/ cells (Figures 6A–6I). In addition, two NF-kB-
related proteins, cRel and p65, but not IkBa, were suppressed
in EP4/ macrophages compared to WT cells (Figure 6J).
Thus, the NF-kB pathway in EP4-null macrophages is signifi-
cantly suppressed.
DISCUSSION
PGs are critical mediators of inflammation, and PGE2 is a major
product of activated macrophages, regulating immune re-
sponses, cytokine production, and apoptosis (Chun et al.,
2007; Nataraj et al., 2001; Takayama et al., 2002; Vassiliou
et al., 2004). PGE2 has been implicated in the pathogenesis of
atherosclerosis, and two of its four receptors, EP2 and EP4,
are expressed in atherosclerotic lesions (Go´mez-Herna´ndez496 Cell Metabolism 8, 492–501, December 3, 2008 ª2008 Elsevieret al., 2006). However, the roles of macrophage EP2 and EP4
have not been previously examined in vivo. Because EP4 defi-
ciency is lethal in mice, we used FLC transplantation to generate
LDLR/ mice chimeric for EP2 or EP4 gene deletions in hema-
topoietic cells. Here we demonstrate that LDLR/ mice recon-
stituted with EP4/ hematopoietic cells had significant de-
creases in atherosclerosis of the proximal and distal aortas
(59% and 71%, respectively) compared to mice transplanted
with WT FLC. EP2 deficiency in hematopoietic cells showed
a trend for similar, but modest, effects on atherosclerosis that
were not statistically significant. Since serum lipid and lipopro-
tein profiles did not differ between the groups, these data
indicate that EP4 deficiency in macrophages is responsible for
reducing early atherosclerosis.
Although COX-2-mediated expression of PGE2 has been
shown to promote cell growth and suppress apoptosis in a vari-
ety of tumors (Backlund et al., 2005; George et al., 2007; Kern
et al., 2006), the roles of PGE2 and its receptors in modulating
macrophage apoptosis in atherogenesis had not been previ-
ously examined. Recently, PGE2 has been reported to mediate
strong prosurvival effects via EP4 and EP2 in epithelial and den-
dritic cells (Tessner et al., 2004; Vassiliou et al., 2004). In our
study, mice reconstituted with EP4/ FLC had a strikingInc.
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sions compared to the recipients with WT hematopoietic cells.
A similar trend for an effect of macrophage EP2 on apoptosis
in atherosclerosis was observed but did not achieve statistical
significance. Our results demonstrate that deficiency of EP4 pro-
motes apoptosis in atherosclerotic lesions in vivo. Because the
gene-targeted mice used in these experiments were derived
from embryonic stem cells of the 129 strain and then crossed
onto the C57BL/6 background, it is possible that passenger
genes from the 129 strain may have contributed to the observed
phenotype (Lusis et al., 2007). As pointed out by Lusis, a contri-
bution of passenger genes is less likely when, as in our study, the
mice have been backcrossed into C57BL/6 strain for ten or more
generations and when the results test a prior hypothesis. Fur-
thermore, our current data are consistent with previous studies
indicating that PGE2 mediates strong prosurvival effects via
EP4 and EP2 in epithelial and dendritic cells (Tessner et al.,
2004; Vassiliou et al., 2004) and suppressed apoptosis in a vari-
ety of tumors (Backlund et al., 2005; George et al., 2007; Kern
et al., 2006).
Apoptosis plays an important role in the development of ath-
erosclerotic lesions and plaque instability (Nhan et al., 2005; Ta-
bas, 2005). In contrast to advanced atherosclerotic lesions char-
acterized by an abundance of apoptotic cells due possibly to
Figure 6. EP4Deficiency in Macrophages Suppresses
NF-kB-Related Gene and Protein Expression Levels
(A–I) Expression levels of inflammatory (IL1b, IL6, MCP1,
MMP9), NF-kB-related (p-50, IKKa, IKKb), and antiapoptotic
(Gadd45b and Itch) genes in WT (black), EP4/ (white), or
EP2/ (gray) macrophages. The cells were treated with LPS
(50 nM) for 5 hr and gene expression levels were measured
by real-time PCR. Graphs represent data (mean ± SEM) of
two experiments with the same number (n = 3) mice per group
(*p < 0.05 between WT and EP4/ cells by one-way ANOVA
analysis).
(J) Protein expression levels in WT and EP4/ macrophages
treated with PA-BSA (500 mM) for 3 and 6 hr. Cell extract
(100 mg/line) was resolved and analyzed by western blot.
The graph represents the data of two different experiments.
defective phagocytic clearance (Kockx, 1998; Ta-
bas, 2005), macrophage apoptosis in the early
stages of atherosclerosis can reduce plaque cellu-
larity and volume. For example, deletion of the
proapoptotic factor Bax in hematopoietic cells sig-
nificantly accelerates early atherosclerosis in
LDLR/ mice (Liu et al., 2005). In agreement with
these findings, when the apoptotic inhibitor AIM
(Spa/Api6 gene) is deleted, LDLR/mice have sig-
nificantly increased macrophage apoptosis and
suppressed early atherosclerosis (Arai et al.,
2005). In addition, mice heterozygous for macro-
phage colony-stimulating factor have a dramatic
(<1% of controls) reduction of atherosclerosis
(Rajavashisth et al., 1998). A recent report demon-
strated that macrophage phospholipase Cb3 defi-
ciency is associated with increased apoptosis in
atherosclerotic lesions and suppression of athero-
sclerosis (Wang et al., 2008). Our present study fur-
ther extends this association between apoptosis and lesion for-
mation by demonstrating that EP4 deficiency in hematopoietic
cells significantly increases macrophage apoptosis and sup-
presses early atherosclerosis. Given that in advanced athero-
sclerotic lesions apoptosis has been implicated in promoting
necrotic cell death and a greater level of plaque instability (Han
et al., 2006; Thorp et al., 2008), it is reasonable to speculate
that macrophage EP4 expression may modulate plaque stability
in advanced lesions. Thus, EP4 and its downstream signaling
pathways may provide new targets for modulating atherogene-
sis and plaque stability.
To examine the hypothesis that macrophage EP4 deficiency
promotes apoptosis, peritoneal macrophages were challenged
with PA-BSA (Borradaile et al., 2006), free cholesterol loading
(Yao and Tabas, 2001), treatment with oxidized LDL, or an inhib-
itor of IkB phosphorylation. All these stimuli induced apoptosis at
higher levels in EP4/ macrophages compared to WT and
EP2/ macrophages. This indicates the importance of EP4 in
macrophage survival signaling. Figure 7 demonstrates that
both EP2 and EP4 receptors may signal through the cAMP/
PKA pathway, inducing phosphorylation of a proapoptotic mem-
ber of the Bcl-2 protein family, Bad at serine 155 (Regan, 2003).
In addition, EP4 activates the PI3K/Akt pathway by phosphory-
lating Bad at two serine residues (serine 112 or 136) (FujinoCell Metabolism 8, 492–501, December 3, 2008 ª2008 Elsevier Inc. 497
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sis by binding antiapoptotic Bcl-2 family members, such as Bcl-
xl, thereby allowing two other proapoptotic members, Bak and
Bax, to form complexes, leading to the release of cytochrome
c, caspase activation, and finally apoptosis (Wei et al., 2001).
In contrast, phosphorylated Bad releases Bcl-xl and binds to
the cytoplasmic anchorage protein, 14-3-3, undergoing cyto-
plasmic sequestration; this protects cells from apoptotic induc-
tion from different stimuli (Bergmann, 2002; Datta et al., 1999).
Here we demonstrate that EP4/ macrophages had signifi-
cantly diminished levels of Akt phosphorylation (Figure 4H). In
addition, Akt completely abolishes the activity of Bad at an early
stage (3 hr) of PA-BSA treatment. Thus, genetic deficiency
of EP4 in macrophages suppresses the PI3K/Akt-signaling
pathway, reducing activation of Bad, which results in increased
apoptosis.
Next we undertook pharmacological experiments to confirm
the relevance of the PI3K/Akt-signaling pathway in mediating
the impact of EP4 deficiency on macrophage apoptosis. The re-
sults strongly support the concept that EP4 deficiency sup-
presses macrophage survival, as treatment with cAMP agonists,
but not with PKA inhibitor H89, reduces phosphorylation of Akt
(Figure 4A). Similarly, only cAMP agonists suppressed phos-
phorylation of Bad155, which is specific for the cAMP/PKA path-
way (Regan, 2003). In contrast, both the PI3K and the Akt inhib-
itors completely abolished p-Akt activation (Figures 5B and 5M)
and dramatically increased apoptosis in macrophages (Figures
5C and 5L). Our data are supported by recent reports demon-
strating that macrophages constitutively express active Akt
(Liu et al., 2001) and that Akt-null macrophages are more sus-
ceptible to apoptosis (Ferna´ndez-Hernando et al., 2007). Corre-
spondingly, the inhibition of the PI3K pathway significantly
accelerates macrophage apoptosis (Liu et al., 2001), and the de-
letion of the PI3K p110 gamma gene significantly inhibits murine
atherosclerosis (Chang et al., 2007). Together, these experi-
ments indicate that activation of the PI3K/Akt pathway is impor-
Figure 7. A Schematic Presentation of the EP2 and
EP4 Receptor-Signaling Pathways Specific for
Mouse Peritoneal Macrophages Relevant to Apo-
ptosis
tant for macrophage survival. The suppression
of this pathway in EP4-null macrophages pro-
motes apoptosis and attenuates the develop-
ment of early atherosclerosis.
In addition to an impact on apoptosis, PGE2
may impact the development and fate of athero-
sclerotic plaques through a variety of mecha-
nisms. For example, the PI3K/Akt pathway has
been shown to be crucial in the regulation of
macrophage chemotaxis and migration (Cur-
nock et al., 2002; Hirsch et al., 2000). EP4 has
been proposed to mediate PGE2-induced pro-
duction of MMP-9 in macrophages (Pavlovic
et al., 2006), and given that apoE/ mice defi-
cient for MMP-9 gene expression have reduced
atherosclerosis with decreased macrophage
infiltration and collagen deposition (Luttun et al., 2004), these
changesmaypromoteplaquedestabilization.Furthermore,PGE2
hasbeenproposed to impact atherosclerosis throughEP4-medi-
ated modulation of inflammation. Pretreatment of bone-marrow-
derived macrophages with PGE2 prior to activation with LPS
results in a transitory attenuation of the early phase of produc-
tion of chemokines and inflammatory cytokines (Minami et al.,
2008). Interestingly, this anti-inflammatory effect is mediated
by a novel EP4 receptor-associated protein that inhibits LPS-in-
duced activation of NF-kB (Minami et al., 2008). In the absence of
pretreatmentwith PGE2,we report that activation of EP4
/mac-
rophageswith LPS results in significant suppressionofNF-kB-re-
sponsive genes and proteins, suggesting that macrophage EP4
may impact atherosclerosis by its effects on inflammatory cyto-
kines such as IL-6 and MCP-1 (Figure 6). These data are consis-
tentwith evidence that activation of Akt can stimulate several sig-
nalingpathways, includingNF-kB (Madrid et al., 2000;Ozeset al.,
1999; Romashkova and Makarov, 1999). The NF-kB activation
may induce transcription of antiapoptotic genes (including
FLIP, the caspase inhibitors cIAP1/2, andBcl-2 familymembers),
changing the balance to prosurvival stimuli (Karin and Lin, 2002)
and increasing the cells’ resistance to apoptosis (Verma and
Mehta, 2007). Thus, the suppression of both the PI3K/Akt and
NF-kB antiapoptotic pathways may synergistically contribute to
the increased apoptosis in EP4/macrophages.
Selective inhibition of COX-2 and nonselective inhibition of
COX by NSAIDs have been reported to increase the risk for car-
diovascular events (Bresalier et al., 2005; Grosser et al., 2006;
Solomon et al., 2005). Macrophage apoptosis has been pro-
posed to promote the formation of unstable plaques and to con-
tribute to plaque rupture (Tabas, 2005). Given that COX-2 inhibi-
tion has been shown to promote apoptosis in a variety of tumors
(Backlund et al., 2005; Kern et al., 2006), it is reasonable to spec-
ulate, based on our current findings, that COX-2 inhibition might
increase apoptosis in atherosclerotic plaques by inhibiting PGE2
production, and its EP4-mediated prosurvival pathways in498 Cell Metabolism 8, 492–501, December 3, 2008 ª2008 Elsevier Inc.
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ture and increased cardiovascular events.
In conclusion, EP4 disruption in macrophages promotes apo-
ptosis and significantly suppresses early atherosclerosis in vivo.
The genetic and pharmacological inhibition of EP4 in macro-
phages suppresses the PI3K/Akt-signaling pathway, reducing
activation of Bad, thereby promoting apoptosis. These data indi-
cate that macrophage EP4 expression plays a crucial role in me-
diating prosurvival signaling. Therefore, the PGE2/EP4 pathway
may provide therapeutic opportunities to modulate the develop-
ment of atherosclerosis and plaque stability.
EXPERIMENTAL PROCEDURES
Animal Procedures
Mice heterozygous for EP4 (Schneider et al., 2004) and EP2 genes (Kennedy
et al., 1999) were on the C57BL/6 background (tenth backcross). Recipient
LDLR/ (on C57BL/6 background) and C57BL/6 mice were purchased from
the Jackson Laboratory (Bar Harbor, ME). Mice were maintained in microiso-
lator cages on a rodent chow diet containing 4.5% fat (PMI 5010, St. Louis,
MO) or aWestern-type diet containing 21%milk fat and 0.15%cholesterol (Te-
klad; Madison, WI). Animal care and experimental procedures were performed
according to the regulations of Vanderbilt University’s Animal Care Committee.
FLC Isolation, Genotyping, and Transplantation
Female EP4+/ (or EP2+/) mice were intercrossed with male EP4+/ (or, re-
spectively, EP2+/) mice, and pregnancy was determined by the presence of
a vaginal plug. On days 14—16 of gestation, embryos were isolated and their
gender was determined by PCR as described (Babaev et al., 1999). To identify
the genotype of EP4/ FLC, a set of primers were generated (AGC GAG TCC
TTA GGC TTT TAA GT, GGA GTC ACT TTC CCT TGA GAA G, and AAC GAG
CCA TTT ACC ACT TGC) and used for PCR analysis (Figure S1Ba). FLCs were
isolated and transplanted (3 3 106) into lethally irradiated (9Gy) recipient
LDLR/ or C57BL6mice as described (Babaev et al., 1999). FLC transplanta-
tion reconstitutes all hematopoietic cell lineages including macrophages and
T and B cells (Forrester et al., 1991).
Serum Lipids and Lipoprotein Distribution Analysis
The serum total cholesterol and triglyceride levels were determined on sam-
ples obtained from mice fasted for 4 hr as described (Fazio et al., 1997).
Fast performance liquid chromatography (FPLC) was performed on an
HPLC system model 600 (Waters, Milford, MA) using a Superose 6 column
(Pharmacia, Piscataway, NJ).
Analysis of Aortic Lesions
Aortas were flushed through the left ventricle, and the entire aorta was dis-
sected for en face analysis as described (Babaev et al., 2005). Cryosections
of the proximal aorta were analyzed using Imaging System KS 300 (Kontron
Electronik GmbH).
Peritoneal Macrophage Isolation and Treatment
Thioglycollate- or concanavalin-A-elicited peritoneal macrophages were iso-
lated as described (Han et al., 2006) from mice reconstituted with wild-type,
EP4/, and EP2/ bone marrow. Two days later, macrophages were treated
with palmitic acid complexed to BSA prepared as described (Borradaile et al.,
2006). Cells were treated with PA-BSA (500 mM) alone or combined with dibu-
tyryl cAMP, RO-20-1724 (100 mM), H89 (10 mM), or wartmannin (all from
Sigma), or Akt inhibitor (EMD, Calbiochem).
Apoptosis Assessment
Serial 5-micron cryosections from the proximal aorta were fixed in 4%parafor-
maldehyde in PBS and treated with 3% citric acid, and apoptotic cells were
detected by the TUNEL (TdT-mediated dUTP nick-end-labeling) technique us-
ing the In Situ Cell Death Detection Kit (Roche Applied Science). After treat-
ment with Fast Red TR/Naphthol AS-NX substrate (Sigma), TUNEL-positive
(TUNEL+) cells were counted in six different sections from each aorta. Perito-Cellneal macrophages were cultured in Laboratory-Tek chamber slides (Nalge
Nunc International). Cells were fixed and treated with 3% citric acid, and
TUNEL+ cells were detected by the In Situ Cell Death Detection Kit.
RNA Isolation and Real-Time PCR
Total RNA was isolated and relative quantitation of the target mRNA was per-
formed as described (Babaev et al., 2007). The gene expression assays
(Applied Biosystems, Foster City, CA) were normalized with 18S ribosomal
RNA as an endogenous control.
Western Blotting
Cells were lysed on ice with a lysis buffer (Cell Signaling Technology, Danvers,
MA) containing a protease (Sigma) and phosphatase (Pierce) inhibitor cock-
tails. Protein concentrations were determined with the DC Protein Assay Kit
(Bio-Rad Laboratories). Lysates (20 or 100 mg/lane) were resolved by NuPAGE
Bis-Tris elecrophoresis (Invitrogen) and transferred onto polyvinylidene di-
fluoride nitrocellulose membranes (Amersham Bioscience). Blots were probed
with rabbit antibodies to Akt, p-Akt, pGSK3a/b, p-Bad136, p-Bad155 (all from
Cell Signaling), c-Rel, NF-kBp65 and IkBa (all fromSantaCruz Biotechnology),
b-actin antibody (Abcam, Inc. Cambridge, MA), and goat anti-rabbit horserad-
ish peroxidase-conjugated secondary antibodies (Upstate Cell Signaling, Lake
Placid, NY). Proteins were visualized with ECL western blotting detection re-
agents (GE Healthcare) on X-ray films. Protein levels were quantified by den-
sitometry normalizing to b-actin.
Statistical Analysis
The statistical differences in mean serum lipids and aortic lesion areas be-
tween the groupswere determined by a one-way ANOVA test using SigmaStat
V.2 (SPSS Inc., Chicago, IL).
SUPPLEMENTAL DATA
Supplemental Data include one table and two figures and can be found
online at http://www.cell.com/cellmetabolism/supplemental/S1550-4131(08)
00289-1.
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